Tvardi Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND, TX, 77478
Mailing Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND, TX, 77478
Phone
(713) 489-8654
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$18.21M
Net Income
$40.83M
Total Liabilities
$20.95M
Stockholders' Equity
$-2.46
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Completed a strategic reverse merger with Cara Therapeutics in April 2025 to secure a Nasdaq listing.
- Lead drug candidate TTI-101 is currently in Phase 2 clinical trials for solid tumors and IPF.
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN
Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB
Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT
Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA
Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN
Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.